Drug Trial Radar · NCT02923739
Paclitaxel and Bevacizumab With or Without Emactuzumab in Treating Patients With Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Last checked: Nov 19, 2026Latest source record: Mar 13, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
9
Actual
Start
May 5, 2017
Primary completion
Sep 27, 2022
Study completion Sep 27, 2022
Sponsor
- Lead sponsor
- M.D. Anderson Cancer CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Cancer Institute (NCI)
- First posted
- Oct 5, 2016
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This randomized phase II trial studies the side effects of paclitaxel and bevacizumab with or without emactuzumab and how well they work in treating patients with ovarian, fallopian tube, or primary peritoneal cancer that has come back after treatment with platinum chemotherapy. Monoclonal antibodies, such as emactuzumab, block tumor growth in different ways by targeting certain cells. Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Bevacizumab may prevent the growth of new blood vessels that tumors need to grow. Giving emactuzumab with paclitaxel and bevacizumab may work better in treating ovarian, fallopian tube, or primary peritoneal cancer.
Conditions
- Fallopian Tube Adenocarcinoma
- Fallopian Tube Clear Cell Adenocarcinoma
- Fallopian Tube Endometrioid Adenocarcinoma
- Fallopian Tube Mucinous Adenocarcinoma
- Fallopian Tube Serous Adenocarcinoma
- Fallopian Tube Transitional Cell Carcinoma
- Fallopian Tube Undifferentiated Carcinoma
- Malignant Ovarian Brenner Tumor
- Ovarian Adenocarcinoma
- Ovarian Clear Cell Adenocarcinoma
- Ovarian Endometrioid Adenocarcinoma
- Ovarian Mucinous Adenocarcinoma
- Ovarian Seromucinous Carcinoma
- Ovarian Serous Adenocarcinoma
- Ovarian Transitional Cell Carcinoma
- Ovarian Undifferentiated Carcinoma
- Primary Peritoneal Serous Adenocarcinoma
- Recurrent Fallopian Tube Carcinoma
- Recurrent Ovarian Carcinoma
- Recurrent Primary Peritoneal Carcinoma
Interventions
BevacizumabBiological
Given IV
EmactuzumabBiological
Given IV
Laboratory Biomarker AnalysisOther
Correlative studies
PaclitaxelDrug
Given IV
Pharmacological StudyOther
Correlative studies
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1: To Evaluate the Safety of Administration of Paclitaxel, Bevacizumab and Emactuzumab Over 4 Weeks.Time frame: Up to 4 weeks
- Part 2B: To Compare the Progression-free Survival (PFS) of Patients With Stable Disease Following Part 2A Randomized to Paclitaxel Plus Bevacizumab or to Paclitaxel, Bevacizumab Plus Emactuzumab.Time frame: At 32 weeks
Locations
8 sites in 1 country. Site status is shown where the registry gives one.
MD Anderson Cancer Center at Cooper-Voorhees
Voorhees Township, New Jersey
UT Southwestern/Simmons Cancer Center-Dallas
Dallas, Texas
M D Anderson Cancer Center
Houston, Texas
The Woman's Hospital of Texas
Houston, Texas
MD Anderson Regional Care Center-Katy
Houston, Texas
MD Anderson Regional Care Center-Bay Area
Nassau Bay, Texas
MD Anderson Regional Care Center-Sugar Land
Sugar Land, Texas
MD Anderson Regional Care Center-The Woodlands
The Woodlands, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.